Product Description
Mechanisms of Action: EGFR Inhibitor,C-Met Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Germany, Hong Kong, Italy, Japan, Singapore, Taiwan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Lung Cancer
Phase 1: Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CEGF816X2102 | P1 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2025-04-21 |
|
| NCT03292133 | P2 |
Active, not recruiting |
Lung Cancer |
2023-12-31 |
|
| jRCT2080224175 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |